First Trust Capital Management L.P. Acquires 23,786 Shares of Bio-Techne Corp $TECH

First Trust Capital Management L.P. acquired a new stake in Bio-Techne Corp (NASDAQ:TECH – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 23,786 shares of the biotechnology company’s stock, valued at approximately $1,724,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Bio-Techne during the 2nd quarter worth $990,924,000. HBK Investments L P purchased a new stake in shares of Bio-Techne during the second quarter worth $482,186,000. Maverick Capital Ltd. raised its position in shares of Bio-Techne by 23.1% in the first quarter. Maverick Capital Ltd. now owns 4,739,721 shares of the biotechnology company’s stock valued at $247,698,000 after buying an additional 888,798 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. raised its position in shares of Bio-Techne by 131.4% in the first quarter. Ruane Cunniff & Goldfarb L.P. now owns 3,392,001 shares of the biotechnology company’s stock valued at $177,266,000 after buying an additional 1,926,066 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Bio-Techne by 10.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,973,136 shares of the biotechnology company’s stock valued at $103,118,000 after buying an additional 178,843 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Price Performance

Shares of NASDAQ:TECH opened at $72.80 on Monday. The business has a fifty day moving average of $72.53 and a two-hundred day moving average of $63.48. The stock has a market cap of $11.44 billion, a P/E ratio of 66.79, a PEG ratio of 5.28 and a beta of 1.29. Bio-Techne Corp has a 52-week low of $43.19 and a 52-week high of $72.88.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.44. Bio-Techne had a return on equity of 13.00% and a net margin of 13.95%. The business had revenue of $299.71 million during the quarter, compared to the consensus estimate of $292.60 million. On average, equities analysts anticipate that Bio-Techne Corp will post 1.75 earnings per share for the current year.

Bio-Techne Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 23rd. Investors of record on Friday, November 13th will be issued a $0.08 dividend. This is a decrease from Bio-Techne’s previous quarterly dividend of $0.65. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 13th. Bio-Techne’s payout ratio is currently 29.36%.

Analyst Ratings Changes

Several research firms have recently weighed in on TECH. Zacks Research raised shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Wells Fargo & Company cut shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $62.00 to $73.00 in a research note on Thursday, August 13th. Weiss Ratings upgraded shares of Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Argus downgraded shares of Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a report on Monday, October 26th. Finally, Benchmark reissued a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $68.92.

Read Our Latest Analysis on Bio-Techne

Bio-Techne Company Profile

(Free Report)

Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.

See Also

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.